Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

摘要

Background:The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.